Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
With
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented colorectal cancer which is EGFR-positive and is metastatic.
Prior irinotecan, alone or in combination, as first-line treatment of metastatic disease.
You may not be if
A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy.
Known dihydropyrimidine dehydrogenase (DPD) deficiency.
Known metastases in the central nervous system.
Symptomatic sensory or peripheral neuropathy.
More than one prior chemotherapy regimen for the treatment of metastatic colorectal cancer.
Prior oxaliplatin therapy.
Prior cetuximab or other therapy which targets the EGF pathway.
Prior chimerized or murine monoclonal antibody therapy.
Clareo Health | Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
